AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+51.26%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$218M
AUM Growth
+$218M
(+0.58%)
Cap. Flow
-$24.1M
Cap. Flow
% of AUM
-11.06%
Top 10 Holdings %
Top 10 Hldgs %
50.64%
Holding
80
New
19
Increased
15
Reduced
12
Closed
11
Top Buys
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$12.9M |
| 2 |
Sanofi
SNY
|
$11.4M |
| 3 |
Establishment Labs
ESTA
|
$8.92M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$8.71M |
| 5 |
AstraZeneca
AZN
|
$6.1M |
Sector Composition
| 1 | Healthcare | 95.13% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $21.4M | 8.41% | 818,035 +4,037 | +0.5% | +$106K |
|
|
2
Madrigal Pharmaceuticals
MDGL
$9.76B
| $20.3M | 7.97% | 70,000 -30,000 | -30% | -$8.71M |
|
|
3
Establishment Labs
ESTA
$1.2B
| $12.5M | 4.91% | 190,767 -135,901 | -42% | -$8.92M |
|
4
Ascendis Pharma
ASND
$11.8B
| $8.67M | 3.4% | 70,997 -29,003 | -29% | -$3.54M |
|
5
BioMarin Pharmaceuticals
BMRN
$11.2B
| $8.28M | 3.25% | +80,000 | New | +$8.28M |
|
|
RXDX
6
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $8.25M | 3.24% | 75,000 +50,000 | +200% | +$5.5M |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $8.17M | 3.2% | 312,498 -37,502 | -11% | -$980K |
|
8
Ventyx Biosciences
VTYX
$171M
| $7.89M | 3.09% | 240,623 +70,623 | +42% | +$2.32M |
|
|
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $7.51M | 2.95% | 280,921 +134,430 | +92% | +$3.6M |
|
10
Arcellx
ACLX
$3.85B
| $7.44M | 2.92% | 240,143 +30,005 | +14% | +$930K |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $7.17M | 2.81% | 1,143,531 -146,980 | -11% | -$922K |
|
12
Astria Therapeutics
ATXS
$349M
| $7.04M | 2.76% | 472,482 +72,439 | +18% | +$1.08M |
|
|
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $6.78M | 2.66% | +215,000 | New | +$6.78M |
|
|
NARI
14
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $5.72M | 2.24% | 90,000 -30,000 | -25% | -$1.91M |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.12M | 2.01% | +45,000 | New | +$5.12M |
|
16
Rocket Pharmaceuticals
RCKT
$354M
| $5.05M | 1.98% | 258,115 -9,679 | -4% | -$189K |
|
17
Celldex Therapeutics
CLDX
$1.47B
| $4.9M | 1.92% | 110,000 +30,000 | +38% | +$1.34M |
|
|
BLU
18
DELISTED
BELLUS Health Inc.
BLU
| $4.72M | 1.85% | 573,678 +100,081 | +21% | +$823K |
|
|
19
AstraZeneca
AZN
$248B
| $4.07M | 1.6% | 60,000 -90,000 | -60% | -$6.1M |
|
20
Cytokinetics
CYTK
$4.23B
| $4.01M | 1.57% | 87,601 +22,601 | +35% | +$1.04M |
|
21
Kura Oncology
KURA
$686M
| $3.34M | 1.31% | 268,747 -407,006 | -60% | -$5.05M |
|
22
Viking Therapeutics
VKTX
$3.04B
| $3.29M | 1.29% | 350,000 +100,000 | +40% | +$940K |
|
23
Lantheus
LNTH
$3.73B
| $3.09M | 1.21% | 60,630 -69,370 | -53% | -$3.54M |
|
24
Vaxcyte
PCVX
$4B
| $2.88M | 1.13% | +60,000 | New | +$2.88M |
|
25
Syndax Pharmaceuticals
SNDX
$1.41B
| $2.55M | 1% | +100,000 | New | +$2.55M |
|